The safety of available pharmacotherapy for stroke prevention in atrial fibrillation

• Published in: Expert opinion on drug safety p. 1
• Main Authors: Denas, G, Santostasi, G, Pengo, V
• Format: Journal Article
• Language: English
• Published: England 01.11.2024
• Subjects: direct oral anticoagulants; atrial fibrillation; Anticoagulant; bleeding; thromboembolism
• ISSN: 1744-764X
• DOI: 10.1080/14740338.2024.2409698

Oral anticoagulant drugs reduce the risk of stroke associated with atrial fibrillation. Vitamin K antagonists, gold standard therapy for decades, have been deposed by the direct oral anticoagulants that exhibit superior safety profiles. However, hemorrhagic complications remain a major concern to anticoagulation. We searched available data in the literature to review the current knowledge on the safety profiles of available anticoagulants. Despite a relevant leap forward with the introduction of DOACs, safety concerns persist in some fields of the current pharmacotherapy for stroke prevention in atrial fibrillation. In-depth knowledge of the safety profile of available anticoagulants and dealing with safety issues in patient subgroups is of utmost importance. Bleeding risk scores should not be dichotomously used to decide anticoagulation treatment but rather to promote shared decision, identify and correct modifiable risk factors, and set monitoring frequency. Additional issues that wait to be investigated in order to improve the safety of therapy include circulating levels of direct oral anticoagulants and anticoagulation in patient sub-groups: very elderly, frail, those with advanced kidney or liver disease, and so on. Safety may be improved from the in-depth knowledge of safety concerns and therapeutic options.